This HTML5 document contains 129 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n12http://dx.doi.org/10.3390/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q100735059
rdf:type
wikibase:Item
schema:description
2020年学术文章 bài báo khoa học мақолаи илмӣ 2020 ވަނަ އަހަރުގެ އޮކްޓޯބަރުމަހުގެ 15ވަނަ ދުވަހު ޝާއިރުކުރެވުނު ލިޔުމެއް vetenskaplig artikel vitskapeleg artikkel articolo scientifico 2020년 논문 artigo científico научни чланак videnskabelig artikel udgivet 15. oktober 2020 2020年學術文章 2020年学术文章 научна статия artículu científicu 2020年學術文章 სამეცნიერო სტატია artykuł naukowy 2020年学术文章 vitenskapelig artikkel artikull shkencor 2020年学术文章 vedecký článok naučni članak artigo científico bilimsel makale teaduslik artikkel 2020年学术文章 บทความทางวิทยาศาสตร์ 2020 nî lūn-bûn artículo científico publicado en 2020 наукова стаття, опублікована в жовтні 2020 article scientifique artigo científico tudományos cikk 2020年学术文章 2020年學術文章 article scientific scienca artikolo scientific article published on 15 October 2020 articol științific מאמר מדעי ১৫ অক্টোবর ২০২০-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ научни чланак επιστημονικό άρθρο 2020年學術文章 im Oktober 2020 veröffentlichter wissenschaftlicher Artikel wetenschappelijk artikel scientific article published on 15 October 2020 article científic 2020年の論文 научная статья vědecký článek مقالة علمية نشرت في 15 أكتوبر 2020 2020年學術文章 tieteellinen artikkeli artikel ilmiah artikulong pang-agham scientific article published on 15 October 2020
p:P577
wds:Q100735059-D4D8BC1B-573E-4005-9923-473A9ADC5C2E
wdt:P577
2020-10-15T00:00:00Z
p:P2093
wds:Q100735059-34DC99A4-4884-4422-857E-738673E4B5D7 wds:Q100735059-A8AA1025-D4F4-49FC-B45C-1253F11A9744 wds:Q100735059-4CCF9CF3-CEE4-4A4D-AA34-294A05B76B5C wds:Q100735059-255D8CE9-F42F-4150-99E3-6D850FE662D8 wds:Q100735059-0F4E1AAA-B3BF-4E31-BFE9-0744ACC659E6 wds:Q100735059-E55DA480-F6A1-4CE0-AE94-84440EBAA1DB wds:Q100735059-D937B5C2-8E61-4EF3-8564-D2A6F4529EBB wds:Q100735059-DF4C1D1B-0A64-4246-989B-45235CC9E8DF wds:Q100735059-EFE34848-60C7-4302-9A5E-7DE50316979F wds:Q100735059-B599A0F4-555B-45E3-A10C-C2C2C3F2584D wds:Q100735059-AE631CD1-77CD-438F-A486-AECC199E3B76 wds:Q100735059-D7400C3A-8F06-4B86-9637-1E384BD51BA3 wds:Q100735059-C32C9C35-EF70-406D-B1FA-6DEB217ECE67
wdt:P2093
Samuel Clark McNeely Rafael Santana-Davila Johanna C Bendell Gu Mi Nicolas Penel Joana M Oliveira Lars Zender Andres O Soriano David Ferry Roy S Herbst Ling Gao Charles S Fuchs Jennifer Cultrera
rdfs:label
Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial
skos:prefLabel
Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial
schema:name
Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial
p:P50
wds:Q100735059-EBDE512E-CD95-4E0D-A343-6873CFBD7AF4 wds:Q100735059-0BC06488-E9F6-4F3D-9CFC-1EEA396C14A8 wds:Q100735059-17D749E8-7703-4473-A65F-D0054F791A2F wds:Q100735059-393D600A-D04F-4626-8C1E-1E00AF17FC59
wdt:P50
wd:Q99549135 wd:Q57014887 wd:Q89775468 wd:Q41608401
p:P1476
wds:Q100735059-34A2B3F6-3B4F-463D-8625-E6EF346F3185
wdt:P1476
Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial
p:P31
wds:Q100735059-B56BB14B-FAA1-4563-AFB7-7CC6229C2A43
wdt:P31
wd:Q13442814
p:P921
wds:Q100735059-47318345-CEF9-4EAB-B0C3-7831A5544F52
wdt:P921
wd:Q13896859
p:P698
wds:Q100735059-0B8786CC-2C88-4A82-BEA9-DA67FBCBA5C3
wdtn:P698
n11:33076423
wdt:P698
33076423
p:P1433
wds:Q100735059-A6A47B22-EBDC-40FA-9A8C-6ADEE8D1C832
wdt:P1433
wd:Q27722963
p:P433
wds:Q100735059-C0A84EBC-F2AF-4E46-AEB0-1235614805DB
p:P478
wds:Q100735059-EF2086E3-7D05-4CB4-BA94-0D7EC7556DE5
wdt:P433
10
wdt:P478
12
p:P356
wds:Q100735059-C4C7A8EB-4563-438B-97C1-16EB46D7A121
wdtn:P356
n12:CANCERS12102985
wdt:P356
10.3390/CANCERS12102985
p:P275
wds:Q100735059-c00f92e8-84b2-450c-9c6e-de85c2d45165
p:P6216
wds:Q100735059-64f51143-e4db-4059-82e6-1e5ffd2777c0
wdt:P275
wd:Q20007257
wdt:P6216
wd:Q50423863
p:P4510
wds:Q100735059-F42C8D21-5792-4CA3-BA90-853541FA3410
wdt:P4510
wd:Q114076227